Archives of Pharmacal Research

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Bactericidal activities of LB20304, a new fluoroquinolone

  • Paek, Kyoung-Sook (Biotech Research Institute, LG Chem Research Park, LG Chemical Ltd) ;
  • Kim, Mu-Yong (Biotech Research Institute, LG Chem Research Park, LG Chemical Ltd) ;
  • Kim, In-Chull (Biotech Research Institute, LG Chem Research Park, LG Chemical Ltd) ;
  • Kwak, Jin-Hwan (Biotech Research Institute, LG Chem Research Park, LG Chemical Ltd)
  • Published : 1996.08.01
Download PDF
⟨ Previous Next ⟩

Abstract

The time-kill curves of LB20304, a novel fluoroquinolone that has potent antibacterial activity against gram-positve and gram-negative bacteria, were calculated at the concentrations of 1/4-, 1/2-, 1-, 2- and 4-times the MIC against Staphylococcus aureus 77, Escherichia coli 3739E, Pseudomonas aeruginosa 1912E. The bactericidal activity of LB20304 for these strains was very rapid and comparable to that of ciprofloxacin. LB20304 produced a decrease in the $log_10$ CFU per milliliter of${\geq}$3 within 2 h at 4-times the MIC for all strains and consitently prevented regrowth of bacteria after 24 h of incubation. The MBCs (Minimal Bactericidal Concentration) of LB20304 against test organisms were equal to or at most four-times higher than the MICs.

Keywords

References

  1. J. Infect. Dis. v.163 Rapid development of ciprofloxacin resistance in methicillin-susceptible and resistant Staphylococcus aureus Blumberg,H.M.;Caroll,D.D.J.;Terry,P.;Wachsmuth,I.K.
  2. Antimicrobial Agents and Chemotheraphy v.35 Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960 and PD-131,628 compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates Fuchs,P.C.;Barry,A.L.;Pfaller,M.A.;Allen,S.D.;Gerlach,E.H.
  3. Quinolone antimicrobial agents Mechanisms of quinolone action and bactericidal killing Hooper,D.C.;Wolfson,J.S.;Hooper,D.C.(ed.);Wolfson,J.S.(ed.)
  4. Drugs v.49 no.Sup.2 Quinolone mode of action Hooper,D.C.
  5. Arch. Pharm. Res. v.19 In vitro activities of LB20304, a new fluoroquinolone Kim,M.Y.;Oh,J.I.;Paek,K.S.;Hong,C.Y.;Kim,I.C.;Kwak,J.H.
  6. M26-T Methods for determining bactericidal activity of antimicrobial agents National Committee for Clinical Laboratory Standards
  7. Approved standard M7-A3 (Third edition) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically National Committee for Clinical Laboratory Standards
  8. In Abstracts of the 35th Interscience Conference on Antimicrobial agents and Chemotherapy In vitro and in vivo antibacterial activities of LB20304, a new fluoronaphthyridone Oh,J.I.;Paek,K.S.;Kim,M.Y.;Seo,S.M.;Lee,Y.H.;Hong,C.Y.;Nam,D.H.;Kim,Y.Z.;Kim,I.C.;Kwak,J.H.
  9. Antimicrobial Agents and Chemotheraphy v.40 In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone Oh,J.I.;Paek,K.S.;Ahn,M.J.;Kim,M.Y.;Hong,C.Y.;Kim,I.C.;Kwak,J.H.
  10. Arch. Pharm. Res. v.19 Factors affecting in vitro activity of LB20304, a new fluoroquinolone Paek,K.S.;Ahn,M.J.;Kim,M.Y.;Kim,I.C.;Kwak,J.H.
  11. Antimicrobial Agents and Chemotheraphy v.38 New quinolones and gram-positive bacteria Piddock,L.J.B.
  12. Antimicrobial Agents and Chemotheraphy v.34 Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital Raviglione,M.C.;Boyle,J.F.;Mariuz,P.;Pablos-Mendez,A.;Cotes,H.;Merlo,A.